CA2556064A1 — 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof, and the use of the same as medicaments
Assigned to Boehringer Ingelheim International GmbH · Expires 2005-09-09 · 21y expired
What this patent protects
The invention relates to substituted xanthines of general formula (I) wherein R1 and R2 have the designations cited in patent claims 1 to 3. The invention also relates to the tautomers, stereoisomers, mixtures and salts of said xanthines, exhibiting valuable pharmacological prope…
USPTO Abstract
The invention relates to substituted xanthines of general formula (I) wherein R1 and R2 have the designations cited in patent claims 1 to 3. The invention also relates to the tautomers, stereoisomers, mixtures and salts of said xanthines, exhibiting valuable pharmacological properties, especially an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.